Main Content
ALS IS A TOUGH DISEASE. IT CALLS FOR AN ORGANIZED AGGRESSIVE APPROACH. WE START BY CONFIRMING THE DIAGNOSIS AND EXCLUDING ALS MIMICS. IF ALS IS CONFIRMED WE USE THE LATEST DISEASE-MODIFYING THERAPIES TO SLOW PROGRESSION. OUR MULTI-DISCIPLINARY TEAM IDENTIFIES SPECIFIC SYMPTOMS AND PROBLEMS AND PROVIDES A WIDE RANGE OF OPTIONS FOR DEALING WITH THEM. WE ARE ALWAYS ON THE LOOKOUT FOR NEW THERAPIES IN OUR ACTIVE RESEARCH PROGRAM. ALL OF US HERE ARE ENTHUSIASTIC AND HOPEFUL!
ALS IS A TOUGH DISEASE. IT CALLS FOR AN ORGANIZED AGGRESSIVE APPROACH. WE START BY CONFIRMING THE DIAGNOSIS AND EXCLUDING ALS MIMICS. IF ALS IS CONFIRMED WE USE THE LATEST DISEASE-MODIFYING THERAPIES TO SLOW PROGRESSION. OUR MULTI-DISCIPLINARY TEAM IDENTIFIES SPECIFIC SYMPTOMS AND PROBLEMS AND PROVIDES A WIDE RANGE OF OPTIONS FOR DEALING WITH THEM. WE ARE ALWAYS ON THE LOOKOUT FOR NEW THERAPIES IN OUR ACTIVE RESEARCH PROGRAM. ALL OF US HERE ARE ENTHUSIASTIC AND HOPEFUL!
Recent and Upcoming Events
September 4, 2024
Drs. Li and Bedlack will present “Overview of Clinical Trils” for the IAMALS Clinical Trials Webinar Series
You can register to watch it HERE
August 23, 2024
Stan Hustad interviews Dr. Bedlack for “Interesting Ideas” podcast
You can listen to it HERE
August 13, 2024
Dr. Bedlack receives inaugural “Accelerating Miracle Progress” Award from Hop On A Cure
Details HERE
July 30, 2024
Duke team publishes first-ever potential explanation for ALS Reversals: mutation in a gene that controls a protein called IGFBP7.
You can read the paper for free HERE
